{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bone+Marrow+Transplant",
    "query": {
      "intervention": "Bone Marrow Transplant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1062,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bone+Marrow+Transplant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T06:15:10.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04803058",
      "title": "A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "TCD601",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ITB-Med LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2022-12-14",
      "completion_date": "2026-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Rochester, Minnesota",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803058"
    },
    {
      "nct_id": "NCT00176826",
      "title": "T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "X-Linked Lymphoproliferative Disorders",
        "Chediak-Higashi Syndrome",
        "Griscelli Syndrome",
        "Immunologic Diseases",
        "Langerhans-Cell Histiocytosis",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Myeloablative conditioning regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2000-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176826"
    },
    {
      "nct_id": "NCT00204958",
      "title": "Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bone Marrow Transplantation",
        "Hematopoietic Stem Cell Transplantion"
      ],
      "interventions": [
        {
          "name": "nutritional supplement",
          "type": "DRUG"
        },
        {
          "name": "glutamine popsicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2004-02",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00204958"
    },
    {
      "nct_id": "NCT00684021",
      "title": "Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Left Ventricular Dysfunction"
      ],
      "interventions": [
        {
          "name": "Adult stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2008-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684021"
    },
    {
      "nct_id": "NCT01660633",
      "title": "Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)",
          "type": "DRUG"
        },
        {
          "name": "Autologous Transplantation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 61,
      "start_date": "2012-12",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660633"
    },
    {
      "nct_id": "NCT05463133",
      "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Pheripheral blood stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emapalumab-Izsg",
          "type": "DRUG"
        },
        {
          "name": "Tociluzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "4 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-08",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463133"
    },
    {
      "nct_id": "NCT04540380",
      "title": "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab",
          "type": "DRUG"
        },
        {
          "name": "Combined bone marrow and kidney transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540380"
    },
    {
      "nct_id": "NCT04263597",
      "title": "Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "2'-fucosyllactose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-08-26",
      "completion_date": "2025-05-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04263597"
    },
    {
      "nct_id": "NCT00005987",
      "title": "Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 87,
      "start_date": "2000-08",
      "completion_date": "2003-07",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005987"
    },
    {
      "nct_id": "NCT00951626",
      "title": "A Standardized Nursing Intervention Protocol for HCT Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Therapy-related Toxicity"
      ],
      "interventions": [
        {
          "name": "exercise intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "dietary intervention",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "standard follow-up care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2005-09",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-09-05T06:15:10.734Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951626"
    }
  ]
}